Genetic polymorphism in a vegf-independent angiogenesis gene angpt1 and overall survival of colorectal cancer patients after surgical resection

PLoS ONE

Volumn 7, Issue 4, 2012, Pages

  Dai, Jingyao ^a   Wan, Shaogui ^b   Zhou, Feng ^c   Myers, Ronald E ^b   Guo, Xu ^d   Li, Bingshan ^e   Fu, Xiaoying ^b   Palazzo, Juan P ^f   Dou, Kefeng ^a   Yang, Hushan ^b   Xing, Jinliang ^d  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

^c FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^d FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^e VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^f THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOT PROTEIN; ANGPT1 PROTEIN; ANTINEOPLASTIC AGENT; DLL4 PROTEIN; ENG PROTEIN; PROTEIN; UNCLASSIFIED DRUG; VASCULOTROPIN; ANGIOPOIETIN 1; ANGPT1 PROTEIN, HUMAN;

ADULT; AGED; AMOT GENE; ANGIOGENESIS; ANGPT1 GENE; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER SURGERY; CANCER SURVIVAL; CHINESE; COLORECTAL CANCER; CONTROLLED STUDY; DLL4 GENE; ENG GENE; FEMALE; GENE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; MALE; SINGLE NUCLEOTIDE POLYMORPHISM; WILD TYPE; ADENOCARCINOMA; ASIAN; COLORECTAL TUMOR; GENETICS; MIDDLE AGED; MORTALITY; MULTIMODALITY CANCER THERAPY; STATISTICS; SURVIVAL;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANGIOPOIETIN-1; ANTINEOPLASTIC AGENTS; ASIAN CONTINENTAL ANCESTRY GROUP; COLORECTAL NEOPLASMS; COMBINED MODALITY THERAPY; FEMALE; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; POLYMORPHISM, SINGLE NUCLEOTIDE; SURVIVAL;

EID: 84859342193     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0034758     Document Type: Article

References (38)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, et al. (2010) Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127: 2893-2917.
2. Ferrari P, Jenab M, Norat T, Moskal A, Slimani N, et al. (2007) Lifetime and baseline alcohol intake and risk of colon and rectal cancers in the European prospective investigation into cancer and nutrition (EPIC). Int J Cancer 121: 2065-2072.
3. Pomerantz MM, Ahmadiyeh N, Jia L, Herman P, Verzi MP, et al. (2009) The 8q24 cancer risk variant rs6983267 shows long-range interaction with MYC in colorectal cancer. Nat Genet 41: 882-884.
4. Tuupanen S, Turunen M, Lehtonen R, Hallikas O, Vanharanta S, et al. (2009) The common colorectal cancer predisposition SNP rs6983267 at chromosome 8q24 confers potential to enhanced Wnt signaling. Nat Genet 41: 885-890.
5. Goel A, Boland CR, (2010) Recent insights into the pathogenesis of colorectal cancer. Curr Opin Gastroenterol 26: 47-52.
6. Chen J, Xie F, Chen K, Wang D, Jiang H, et al. (2009) ERCC5 promoter polymorphisms at -763 and +25 predict the response to oxaliplatin-based chemotherapy in patients with advanced colorectal cancer. Cancer Biol Ther 8: 1424-1430.
7. Ulrich CM, Robien K, McLeod HL, (2003) Cancer pharmacogenetics: polymorphisms, pathways and beyond. Nat Rev Cancer 3: 912-920.
8. Castro FA, Forsti A, Buch S, Kalthoff H, Krauss C, et al. (2011) TLR-3 polymorphism is an independent prognostic marker for stage II colorectal cancer. Eur J Cancer 47: 1203-1210.
9. Xing J, Myers RE, He X, Qu F, Zhou F, et al. (2011) GWAS-identified colorectal cancer susceptibility locus associates with disease prognosis. Eur J Cancer 47: 1699-1707.
10. Rmali KA, Puntis MC, Jiang WG, (2007) Tumour-associated angiogenesis in human colorectal cancer. Colorectal Dis 9: 3-14.
11. Yancopoulos GD, Davis S, Gale NW, Rudge JS, Wiegand SJ, et al. (2000) Vascular-specific growth factors and blood vessel formation. Nature 407: 242-248.
12. Shibuya M, (2008) Vascular endothelial growth factor-dependent and-independent regulation of angiogenesis. BMB Rep 41: 278-286.
13. Bergers G, Hanahan D, (2008) Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 8: 592-603.
14. Dufraine J, Funahashi Y, Kitajewski J, (2008) Notch signaling regulates tumor angiogenesis by diverse mechanisms. Oncogene 27: 5132-5137.
15. Loughna S, Sato TN, (2001) Angiopoietin and Tie signaling pathways in vascular development. Matrix Biol 20: 319-325.
16. Levchenko T, Veitonmaki N, Lundkvist A, Gerhardt H, Ming Y, et al. (2008) Therapeutic antibodies targeting angiomotin inhibit angiogenesis in vivo. FASEB J 22: 880-889.
17. El-Gohary YM, Silverman JF, Olson PR, Liu YL, Cohen JK, et al. (2007) Endoglin (CD105) and vascular endothelial growth factor as prognostic markers in prostatic adenocarcinoma. Am J Clin Pathol 127: 572-579.
18. Koukourakis MI, Papazoglou D, Giatromanolaki A, Bougioukas G, Maltezos E, et al. (2004) VEGF gene sequence variation defines VEGF gene expression status and angiogenic activity in non-small cell lung cancer. Lung Cancer 46: 293-298.
19. Yang B, Cross DF, Ollerenshaw M, Millward BA, Demaine AG, (2003) Polymorphisms of the vascular endothelial growth factor and susceptibility to diabetic microvascular complications in patients with type 1 diabetes mellitus. J Diabetes Complications 17: 1-6.
20. Renner W, Kotschan S, Hoffmann C, Obermayer-Pietsch B, Pilger E, (2000) A common 936 C/T mutation in the gene for vascular endothelial growth factor is associated with vascular endothelial growth factor plasma levels. J Vasc Res 37: 443-448.
21. Dassoulas K, Gazouli M, Rizos S, Theodoropoulos G, Christoni Z, et al. (2009) Common polymorphisms in the vascular endothelial growth factor gene and colorectal cancer development, prognosis, and survival. Mol Carcinog 48: 563-569.
22. Hofmann G, Langsenlehner U, Renner W, Langsenlehner T, Yazdani-Biuki B, et al. (2008) Common single nucleotide polymorphisms in the vascular endothelial growth factor gene and colorectal cancer risk. J Cancer Res Clin Oncol 134: 591-595.
23. Hansen TF, Spindler KL, Lorentzen KA, Olsen DA, Andersen RF, et al. (2010) The importance of -460 C/T and +405 G/C single nucleotide polymorphisms to the function of vascular endothelial growth factor A in colorectal cancer. J Cancer Res Clin Oncol 136: 751-758.
24. Cai J, Han S, Qing R, Liao D, Law B, et al. (2011) In pursuit of new anti-angiogenic therapies for cancer treatment. Front Biosci 16: 803-814.
25. Huang H, Bhat A, Woodnutt G, Lappe R, (2010) Targeting the ANGPT-TIE2 pathway in malignancy. Nat Rev Cancer 10: 575-585.
26. Shim WS, Ho IA, Wong PE, (2007) Angiopoietin: a TIE(d) balance in tumor angiogenesis. Mol Cancer Res 5: 655-665.
27. Papapetropoulos A, Fulton D, Mahboubi K, Kalb RG, O'Connor DS, et al. (2000) Angiopoietin-1 inhibits endothelial cell apoptosis via the Akt/survivin pathway. J Biol Chem 275: 9102-9105.
28. Maisonpierre PC, Suri C, Jones PF, Bartunkova S, Wiegand SJ, et al. (1997) Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science 277: 55-60.
29. Asahara T, Chen D, Takahashi T, Fujikawa K, Kearney M, et al. (1998) Tie2 receptor ligands, angiopoietin-1 and angiopoietin-2, modulate VEGF-induced postnatal neovascularization. Circ Res 83: 233-240.
30. Holash J, Maisonpierre PC, Compton D, Boland P, Alexander CR, et al. (1999) Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science 284: 1994-1998.
31. Hayes AJ, Huang WQ, Yu J, Maisonpierre PC, Liu A, et al. (2000) Expression and function of angiopoietin-1 in breast cancer. Br J Cancer 83: 1154-1160.
32. Stoeltzing O, Ahmad SA, Liu W, McCarty MF, Wey JS, et al. (2003) Angiopoietin-1 inhibits vascular permeability, angiogenesis, and growth of hepatic colon cancer tumors. Cancer Res 63: 3370-3377.
33. Yu Q, Stamenkovic I, (2001) Angiopoietin-2 is implicated in the regulation of tumor angiogenesis. Am J Pathol 158: 563-570.
34. Hawighorst T, Skobe M, Streit M, Hong YK, Velasco P, et al. (2002) Activation of the tie2 receptor by angiopoietin-1 enhances tumor vessel maturation and impairs squamous cell carcinoma growth. Am J Pathol 160: 1381-1392.
35. Thompson SD, Sudman M, Ramos PS, Marion MC, Ryan M, et al. (2010) The susceptibility loci juvenile idiopathic arthritis shares with other autoimmune diseases extend to PTPN2, COG6, and ANGPT1. Arthritis Rheum 62: 3265-3276.
36. Roberts KE, Fallon MB, Krowka MJ, Brown RS, Trotter JF, et al. (2009) Genetic risk factors for portopulmonary hypertension in patients with advanced liver disease. Am J Respir Crit Care Med 179: 835-842.
37. Bao L, Zhou M, Wu L, Lu L, Goldowitz D, et al. (2007) PolymiRTS Database: linking polymorphisms in microRNA target sites with complex traits. Nucleic Acids Res 35: D51-54.
38. Mita AC, Takimoto CH, Mita M, Tolcher A, Sankhala K, et al. (2010) Phase 1 study of AMG 386, a selective angiopoietin 1/2-neutralizing peptibody, in combination with chemotherapy in adults with advanced solid tumors. Clin Cancer Res 16: 3044-3056.